Management of Coagulopathy in Patients with Decompensated Liver Cirrhosis

Patients with decompensated liver cirrhosis have significantly impaired synthetic function. Many proteins involved in the coagulation process are synthesized in the liver. Routinely performed tests of the coagulation are abnormal in patients with decompensated liver cirrhosis. This has led to the wi...

Full description

Saved in:
Bibliographic Details
Main Authors: Pooja D. Amarapurkar, Deepak N. Amarapurkar
Format: Article
Language:English
Published: Wiley 2011-01-01
Series:International Journal of Hepatology
Online Access:http://dx.doi.org/10.4061/2011/695470
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832561052792913920
author Pooja D. Amarapurkar
Deepak N. Amarapurkar
author_facet Pooja D. Amarapurkar
Deepak N. Amarapurkar
author_sort Pooja D. Amarapurkar
collection DOAJ
description Patients with decompensated liver cirrhosis have significantly impaired synthetic function. Many proteins involved in the coagulation process are synthesized in the liver. Routinely performed tests of the coagulation are abnormal in patients with decompensated liver cirrhosis. This has led to the widespread belief that decompensated liver cirrhosis is prototype of acquired hemorrhagic coagulopathy. If prothrombin time is prolonged more than 3 seconds over control, invasive procedures like liver biopsy, splenoportogram, percutaneous cholangiography, or surgery were associated with increased risk of bleeding, and coagulopathy should be corrected with infusion of fresh frozen plasma. These practices were without any scientific evidence and were associated with significant hazards of fresh frozen plasma transfusion. Now, it is realized that coagulation is a complex process involving the interaction of procoagulation and anticoagulation factors and the fibrinolytic system. As there is reduction in both anti and procoagulant factors, global tests of coagulation are normal in patients with acute and chronic liver disease indicating that coagulopathy in liver disease is more of a myth than a reality. In the last few years, surgical techniques have substantially improved, and complex procedures like liver transplantation can be done without the use of blood or blood products. Patients with liver cirrhosis may also be at increased risk of thrombosis. In this paper, we will discuss coagulopathy, increased risk of thrombosis, and their management in decompensated liver cirrhosis.
format Article
id doaj-art-f49ad2b09e124a778fcd99c9101e24cb
institution Kabale University
issn 2090-3448
2090-3456
language English
publishDate 2011-01-01
publisher Wiley
record_format Article
series International Journal of Hepatology
spelling doaj-art-f49ad2b09e124a778fcd99c9101e24cb2025-02-03T01:26:12ZengWileyInternational Journal of Hepatology2090-34482090-34562011-01-01201110.4061/2011/695470695470Management of Coagulopathy in Patients with Decompensated Liver CirrhosisPooja D. Amarapurkar0Deepak N. Amarapurkar1Department of Gastroenterology, Bombay Hospital and Medical Research Centre, Mumbai 400 020, IndiaAmeya Co-Op Housing Society, New Prabhadevi Road, Prabhadevi, Mumbai 400 025, IndiaPatients with decompensated liver cirrhosis have significantly impaired synthetic function. Many proteins involved in the coagulation process are synthesized in the liver. Routinely performed tests of the coagulation are abnormal in patients with decompensated liver cirrhosis. This has led to the widespread belief that decompensated liver cirrhosis is prototype of acquired hemorrhagic coagulopathy. If prothrombin time is prolonged more than 3 seconds over control, invasive procedures like liver biopsy, splenoportogram, percutaneous cholangiography, or surgery were associated with increased risk of bleeding, and coagulopathy should be corrected with infusion of fresh frozen plasma. These practices were without any scientific evidence and were associated with significant hazards of fresh frozen plasma transfusion. Now, it is realized that coagulation is a complex process involving the interaction of procoagulation and anticoagulation factors and the fibrinolytic system. As there is reduction in both anti and procoagulant factors, global tests of coagulation are normal in patients with acute and chronic liver disease indicating that coagulopathy in liver disease is more of a myth than a reality. In the last few years, surgical techniques have substantially improved, and complex procedures like liver transplantation can be done without the use of blood or blood products. Patients with liver cirrhosis may also be at increased risk of thrombosis. In this paper, we will discuss coagulopathy, increased risk of thrombosis, and their management in decompensated liver cirrhosis.http://dx.doi.org/10.4061/2011/695470
spellingShingle Pooja D. Amarapurkar
Deepak N. Amarapurkar
Management of Coagulopathy in Patients with Decompensated Liver Cirrhosis
International Journal of Hepatology
title Management of Coagulopathy in Patients with Decompensated Liver Cirrhosis
title_full Management of Coagulopathy in Patients with Decompensated Liver Cirrhosis
title_fullStr Management of Coagulopathy in Patients with Decompensated Liver Cirrhosis
title_full_unstemmed Management of Coagulopathy in Patients with Decompensated Liver Cirrhosis
title_short Management of Coagulopathy in Patients with Decompensated Liver Cirrhosis
title_sort management of coagulopathy in patients with decompensated liver cirrhosis
url http://dx.doi.org/10.4061/2011/695470
work_keys_str_mv AT poojadamarapurkar managementofcoagulopathyinpatientswithdecompensatedlivercirrhosis
AT deepaknamarapurkar managementofcoagulopathyinpatientswithdecompensatedlivercirrhosis